Modality
Gene Therapy
MOA
WEE1i
Target
CD20
Pathway
Amyloid
Celiac
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
~Oct 2022
→ ~Jan 2024
NDA/BLA
Apr 2024
→ Mar 2029
NDA/BLACurrent
NCT06729102
2,493 pts·Celiac
2024-04→2029-03·Recruiting
2,493 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-173.0y awayPh3 Readout· Celiac
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-03-17 · 3.0y away
Celiac
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06729102 | NDA/BLA | Celiac | Recruiting | 2493 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR | |
| Motanaritide | Intellia | Approved | PD-1 |